Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 9, 2009, Pages 664-669

  Hockenberry, Marilyn J ^a,d   Hooke, Mary C ^c   Gregurich, Maryann ^b   McCarthy, Kathy ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^d Center for Research and Evidence Based Practice   (United States)

Author keywords

Carnitine; Chemotherapy; Childhood cancer; Fatigue

Indexed keywords

CARNITINE; CISPLATIN; DOXORUBICIN; IFOSFAMIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARNITINE; CHILD; CISPLATIN; COHORT STUDIES; DOXORUBICIN; ENERGY METABOLISM; FATIGUE; FEMALE; HUMANS; IFOSFAMIDE; MALE; NEOPLASMS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 70349145429     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b259a7     Document Type: Article

References (32)

1. Symptom management in cancer: pain, depression, and fatigue. NIH Consens State Sci Statements. 2002;19:1-29.
2. Hedstrom M, Haglund K, Skolin I, et al. Distressing events for children and adolescents with cancer: child, parent, and nurse perceptions. J Pediatr Oncol Nurs. 2003;20:120-132.
3. Collins JJ, Byrnes ME, Dunkel IJ, et al. The measurement of symptoms in children with cancer. J Pain Symptom Manage. 2000;19:363-377.
4. Woodgate RL, Degner LF. Expectations and beliefs about children's cancer symptoms: perspectives of children with cancer and their families. Oncol Nurs Forum. 2003;30:479-491.
5. Docherty SL. Symptom experiences of children and adolescents with cancer. Annu Rev Nurs Res. 2003;21:123-149.
6. Hockenberry-Eaton M, Hinds PS, Alcoser P, et al. Fatigue in children and adolescents with cancer. J Pediatr Oncol Nurs. 1998;15:172-182.
7. Hockenberry-Eaton M, Hinds P, Howard V, et al. Developing a conceptual model for fatigue in children. Eur J Oncol Nurs. 1999;3:5-11.
8. Hockenberry-Eaton M, Hinds PS. Fatigue in children and adolescents with cancer. In: Winningham ML, Barton-Burke M, eds. Fatigue in Cancer. Studbery: Jones and Bartlett Publishers; 2000:71-85.
9. Hockenberry MJ, Hinds PS, Barrera P, et al. Three instruments to assess fatigue in children with cancer: the child, parent and staff perspectives. J Pain Symptom Manage. 2003;25: 319-328.
10. Hare ML, Hinds PS, Stewart JL. Moving the research agenda forward for children and adolescents with cancer. J Pediatr Oncol Nurs. 2004;21:186-188.
11. Dimeo FC. Effects of exercise on cancer-related fatigue. Cancer. 2001;92:1689-1693.
12. Gutstein HB. The biologic basis of fatigue. Cancer. 2001;92: 1678-1683.
13. NCCN (National Comprehensive Cancer Network). Cancer related fatigue. Clinical Practice Guidelines in Oncology- v1.2008. Available at: http://www.nccn.org/professionals/physician-gls/PDF/fatigue.pdf Accessed April 10, 2008.
14. Peluso G, Nicolai R, Reda E, et al. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol. 2000;182:339-350.
15. DeGrandis D. Acetyl-L-carnitine for the treatment of chemotherapy- induced peripheral neuropathy: a short review. CNS Drugs. 2007;21:39-43.
16. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann NY Acad Sci. 2004;1033:30-41.
17. Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy- induced fatigue in non-anaemic cancer patients. Br J Cancer. 2002;86:1854-1857.
18. Waldner R, Laschan C, Lohninger A, et al. Effects of doxorubicin- containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res Clin Oncol. 2006;132: 121-128.
19. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatininduced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005;41:1746-1750.
20. Kawasaki N, Lee JD, Shimizu H, et al. Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats. Int J Cardiol. 1996;55:217-225.
21. Abdel-aleem S, el-Merzabani MM, Sayed-Ahmed M, et al. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol. 1997;29: 789-797.
22. Neri B, Cini-Neri G, Bartalucci S, et al. Protective effect of L-carnitine on cardiac metabolic damage induced by doxorubicin in vito. Anticancer Res. 1986;6:659-662.
23. Cruciani R, Dvorkin E, Homel P, et al. Safety, tolerability, & symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carntine deficiency: a phase I/II study. J Pain Symptom Manage. 2006;32:551-559.
24. National Institutes of Health. Phase III randomized study of levocarnitine (L-carnitine) for the management of fatigue in cancer patients. Clinical Trials.gov. Available at: http://www.cancer.gov/clinicaltrials/ECOG- E4Z02. Accessed January 26, 2009
25. Yaris N, Akyuz C, Coskun T, et al. Serum carnitine levels of pediatric cancer patients. Pediatr Hematol Oncol. 2002;19:1-8.
26. Hinds PS, Hockenberry M, Tong X, et al. Validity and reliability of a new instrument to measure cancer-related fatigue in adolescents. J Pain Symptom Manage. 2007;34: 607-618.
27. Schmidt-Sommerfeld E, Werner D, Penn D. Carnitine plasma concentrations in 353 metabolically healthy children. Eur J Pediatr. 1988;147:356-360.
28. Hinds PS, Hockenberry-Eaton M, Gilger E, et al. Comparing patient, parent, and staff descriptions of fatigue in pediatric oncology patients. Cancer Nurs. 1999;22:277-288.
29. Heuberger W, Beradi S, Jacky E, et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol. 1998;54:503-508.
30. Cruciano R, Dvorkin E, Homel P, et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage. 2009;37:622-631.
31. Taketoma CK, Hodding JK, Kraus DM. Pediatric Dosage Handbook. 15th ed. Cleveland, OH: Lexi-Comp Inc; 2008.
32. Alesci S, DeMartino MU, Kino T, et al. L-carnitine is a modulator of the glucocorticoid receptor alpha. Ann NY Acad Sci. 2004;1024:147-152. (Pubitemid 38879599)